Barclays
KNSA icon

Barclays’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Barclays’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.64M Buy
34,152
+29,575
+646% +$1.31M ﹤0.01% 2480
2025
Q4 		$189K Sell
4,577
-2,776
-38% -$111K ﹤0.01% 4354
2025
Q3 		$286K Sell
7,353
-4,699
-39% -$153K ﹤0.01% 4137
2025
Q2 		$333K Sell
12,052
-43,291
-78% -$1.1M ﹤0.01% 3987
2025
Q1 		$1.23M Sell
55,343
-16,553
-23% -$341K ﹤0.01% 2978
2024
Q4 		$1.42M Buy
71,896
+7,267
+11% +$166K ﹤0.01% 3143
2024
Q3 		$1.62M Buy
64,629
+29,790
+86% +$726K ﹤0.01% 3027
2024
Q2 		$650K Sell
34,839
-7,308
-17% -$137K ﹤0.01% 2876
2024
Q1 		$832K Sell
42,147
-143,609
-77% -$2.8M ﹤0.01% 3264
2023
Q4 		$3.26M Buy
185,756
+10,231
+6% +$168K ﹤0.01% 2490
2023
Q3 		$3.05M Buy
175,525
+12,867
+8% +$217K ﹤0.01% 1640
2023
Q2 		$2.29M Buy
162,658
+479
+0.3% +$6.41K ﹤0.01% 1803
2023
Q1 		$1.75M Buy
162,179
+102,172
+170% +$1.35M ﹤0.01% 2292
2022
Q4 		$899K Buy
60,007
+37,666
+169% +$548K ﹤0.01% 2893
2022
Q3 		$287K Buy
22,341
+5,969
+36% +$68K ﹤0.01% 3003
2022
Q2 		$158K Sell
16,372
-3,289
-17% -$30.7K ﹤0.01% 3560
2022
Q1 		$195K Sell
19,661
-35,873
-65% -$380K ﹤0.01% 3439
2021
Q4 		$653K Sell
55,534
-21,026
-27% -$258K ﹤0.01% 3071
2021
Q3 		$872K Buy
76,560
+56,731
+286% +$739K ﹤0.01% 2866
2021
Q2 		$275K Sell
19,829
-235,707
-92% -$3.58M ﹤0.01% 3409
2021
Q1 		$4.73M Sell
255,536
-425,364
-62% -$8.7M ﹤0.01% 1565
2020
Q4 		$12M Buy
680,900
+392,512
+136% +$6.89M 0.01% 1080
2020
Q3 		$4.42M Buy
288,388
+271,796
+1,638% +$5.1M ﹤0.01% 1478
2020
Q2 		$423K Buy
16,592
+10,367
+167% +$217K ﹤0.01% 3472
2020
Q1 		$97K Sell
6,225
-12,058
-66% -$189K ﹤0.01% 4826
2019
Q4 		$202K Buy
18,283
+6,864
+60% +$59.6K ﹤0.01% 5020
2019
Q3 		$98K Buy
11,419
+264
+2% +$2.92K ﹤0.01% 5494
2019
Q2 		$151K Buy
11,155
+6,790
+156% +$105K ﹤0.01% 5357
2019
Q1 		$80K Buy
4,365
+1,311
+43% +$25.3K ﹤0.01% 5537
2018
Q4 		$86K Buy
3,054
+624
+26% +$13K ﹤0.01% 5145
2018
Q3 		$62K Buy
+2,430
New +$47.3K ﹤0.01% 5933

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Barclays's KNSA Position: Q1 2026 in Review

Barclays increased its Kiniksa Pharmaceuticals (KNSA) stake by 646% in Q1 2026, buying an estimated $1.31M and bringing the position to 34,152 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #2480.

Barclays first reported a position in KNSA in Q3 2018 and has held it in 31 quarters since. The position peaked at $12M in Q4 2020. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Barclays held 34,152 shares of Kiniksa Pharmaceuticals worth $1.64M as of Q1 2026.
  • Barclays bought 29,575 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $1.31M.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2480 holding.
  • Barclays first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • Barclays's Kiniksa Pharmaceuticals position peaked at $12M in Q4 2020.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.